Finally, chiropractors should evaluate whether patients undergoing androgen deprivation
therapy is a relative risk for spinal manipulative therapy.
Radical prostatectomy and/or radiotherapy are the treatment modalities adopted for organ confined prostate cancer however androgen deprivation
therapy (ADT) is the essential part of standard treatment for men with advanced prostate cancer3.
The team's hypothesis is that metastatic prostate cancer patients with the weakest response to androgen-deprivation therapy could be given GCP concurrently with androgen deprivation
therapy to retain Filamin A in the nucleus, thereby allowing cancer cells to die off.
This is also referred to as complete androgen deprivation
therapy: reduces levels of androgens in the body, slowing the growth of prostate cancers; achieved through orchiectomy, luteinizing hormone-releasing hormone analogs or antagonists, or antiandrogens
This population-based cohort study examined whether androgen deprivation
therapy (orchiectomy or luteinizing hormone-releasing hormone) is associated with improved survival among elderly men with localized prostate cancer, when compared with conservative management (i.
Improvements in bone mineral density in men with prostate cancer on androgen deprivation
are greatest in men who continue to receive alendronate therapy," Greenspan's group concludes.
Many men with prostate cancer receive treatment with primary androgen deprivation
therapy (PADT) as an alternative to surgery, radiation, or other traditional forms of treatment.
Following therapy for prostate cancer, it is critical that the clinician provide the pertinent history of androgen deprivation
or radiation therapy to assist the pathologist in rendering the correct diagnosis.
the Men's Health Biotech Company, has announced the results of a lipid interim analysis of the pivotal Phase III ADT clinical trial evaluating oral, once daily ACAPODENE(R) (toremifene citrate) 80mg for the treatment of the multiple serious side effects of androgen deprivation
therapy (ADT) in men with advanced prostate cancer.
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation
therapy failure in prostate cancer.
Food and Drug Administration (FDA) for the potential treatment of metastatic castration-resistant prostate cancer (CRPC), an advanced and difficult-to-treat form of prostate cancer that occurs when the disease progresses despite the use of androgen deprivation